ctDNA-Guided Immunotherapy Shows Promising Results to Reduce Overtreatment and Improve Outcomes for Patients with Bladder Cancer

The Danish TOMBOLA trial aims to use ctDNA as a better predictor of recurrence than conventional risk factors in patients with muscle-invasive bladder cancer. Jørgen Bjerggaard Jensen presented the results at ESMO 2024, and the preliminary results suggest that ctDNA-guided immunotherapy could significantly reduce overtreatment and improve outcomes. The trial is moving toward implementing this at Aarhus University Hospital.